EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurokinin‐1 receptor antagonist (maropitant) for treatment of chronic idiopathic rhinitis in dogs: a pilot study

H Neittaanmäki iD, M Rajamäki, N Airas, A Tilamaa, S Viitanen iD

Journal of Small Animal Practice · 30.10.2026

DOI: 10.1111/jsap.70218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Small Animal Practice, online erschienen am 30.10.2026. Verfasst von H Neittaanmäki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suomen Eläinlääketieteen Säätiö, Eläinlääketieteen Tutkimuksen Tukisäätiö.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Chronic idiopathic rhinitis is a common canine nasal disease with unknown aetiology and poor response to treatment. Neurokinin‐1 receptor activation has been associated with rhinitis in experimental animals. The aim of this pilot study was to compare the effects of oral neurokinin‐1 receptor antagonist (maropitant) with placebo on clinical signs of chronic idiopathic rhinitis in dogs. Materials and Methods Prospective randomised placebo‐controlled double‐blinded pilot trial. Eighteen privately owned dogs diagnosed with chronic idiopathic rhinitis based on clinical presentation, CT, rhinoscopy and histopathological findings were randomised to receive either maropitant 2 mg/kg ( n = 9) or placebo ( n = 9) orally, every other day for 4 weeks. Disease severity was assessed using study‐specific scoring systems for CT and histopathological findings and derived from a validated questionnaire for nasal and gastrointestinal clinical signs. Each score was compared between groups at baseline. Response to treatment was assessed weekly by comparing the nasal and gastrointestinal scores between groups.

Results

Severity scores were similar between groups at baseline. Nasal scores did not differ significantly between treatment and placebo groups at the end of the trial [week 4; difference in least square means: −0.59, 95% CI −2.9 to 1.7]. The treatment group's mean score was 5.7 (range 1 to 11) at week 0 and 4.9 (range 0 to 12) at week 4, with no statistically significant change (least square means: −0.9, 95% CI −2.6 to 0.74). Clinical Significance Alternate‐day oral administration of maropitant 2 mg/kg in dogs with chronic idiopathic rhinitis did not result in a clinically relevant reduction in clinical signs.

Autor:innen und Institutionen

  • Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
  • Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.

ORCID-Profile: H Neittaanmäki, S Viitanen

Förderung

  • Suomen Eläinlääketieteen Säätiö
  • Eläinlääketieteen Tutkimuksen Tukisäätiö

Zitieren

APA

Neittaanmäki, H., Rajamäki, M., Airas, N., Tilamaa, A., & Viitanen, S. (2026). Neurokinin‐1 receptor antagonist (maropitant) for treatment of chronic idiopathic rhinitis in dogs: a pilot study. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.70218

Vancouver

Neittaanmäki H, Rajamäki M, Airas N, Tilamaa A, Viitanen S. Neurokinin‐1 receptor antagonist (maropitant) for treatment of chronic idiopathic rhinitis in dogs: a pilot study. Journal of Small Animal Practice. 2026. doi:10.1111/jsap.70218

BibTeX
@article{Neittaanmki2026,
  author = {Neittaanmäki, H and Rajamäki, M and Airas, N and Tilamaa, A and Viitanen, S},
  title = {Neurokinin‐1 receptor antagonist (maropitant) for treatment of chronic idiopathic rhinitis in dogs: a pilot study},
  journal = {Journal of Small Animal Practice},
  year = {2026},
  doi = {10.1111/jsap.70218}
}
Kostenlos starten →